tgAAC94 gene therapy / Armata, Amgen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tgAAC94 gene therapy / Armata, Amgen
NCT00617032: Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

Completed
1
15
US, Canada
tgAAC94 gene therapy vector, tgAAC94 placebo
Targeted Genetics Corporation
Rheumatoid Arthritis
11/05
11/05

Download Options